Sarepta Therapeutics, Inc.
US ˙ NasdaqGS ˙ US8036071004

SecuritySRPT / Sarepta Therapeutics, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership2,146 shares
Latest Disclosed Value $ 36,696
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 58.61% increase in ownership of SRPT / Sarepta Therapeutics, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 2,146 shares of Sarepta Therapeutics, Inc. (US:SRPT) valued at $36,697 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 1,353 shares of Sarepta Therapeutics, Inc.. This represents a change in shares of 58.61% during the quarter. The current value of the position is $35,752 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Sarepta Therapeutics EC US8036071004 2,146 793 58.61 37 -58.14 0.4078
2025-05-29 2025-03-31 NP Sarepta Therapeutics EC US8036071004 1,353 120 9.73 86 -42.28 0.9173
2025-03-03 2024-12-31 NP Sarepta Therapeutics EC US8036071004 1,233 -138 -10.07 150 -12.87 1.5029
2024-11-29 2024-09-30 NP Sarepta Therapeutics EC US8036071004 1,371 10 0.73 171 -20.47 1.5509
2024-08-29 2024-06-30 NP Sarepta Therapeutics EC US8036071004 1,361 -260 -16.04 215 2.87 1.9604
2024-05-30 2024-03-31 NP Sarepta Therapeutics EC US8036071004 1,621 -147 -8.31 210 22.94 1.7797
2024-02-29 2023-12-31 NP Sarepta Therapeutics EC US8036071004 1,768 57 3.33 170 -17.87 1.3973
2023-11-29 2023-09-30 NP Sarepta Therapeutics EC US8036071004 1,711 -25 -1.44 207 4.55 1.7958
2023-08-28 2023-06-30 NP Sarepta Therapeutics EC US8036071004 1,736 184 11.86 199 -7.04 1.5689
2023-05-30 2023-03-31 NP Sarepta Therapeutics EC US8036071004 1,552 -757 -32.78 214 -28.76 1.6202
2023-02-28 2022-12-31 NP Sarepta Therapeutics EC US8036071004 2,309 227 10.90 299 30.00 1.8094
2022-11-29 2022-09-30 NP Sarepta Therapeutics EC US8036071004 2,082 -670 -24.35 230 11.65 1.6061
2022-08-29 2022-06-30 NP Sarepta Therapeutics EC US8036071004 2,752 -70 -2.48 206 -6.36 1.4152
2022-05-26 2022-03-31 NP Sarepta Therapeutics EC US8036071004 2,822 -288 -9.26 220 -21.43 1.3027
2022-02-28 2021-12-31 NP Sarepta Therapeutics EC US8036071004 3,110 311 11.11 280 8.53 1.2375
2021-11-29 2021-09-30 NP Sarepta Therapeutics EC US8036071004 2,799 -195 -6.51 259 11.21 1.0881
2021-08-27 2021-06-30 NP Sarepta Therapeutics EC US8036071004 2,994 -37 -1.22 233 3.11 0.9748
2021-05-27 2021-03-31 NP Sarepta Therapeutics EC US8036071004 3,031 648 27.19 226 -44.58 1.0165
2021-03-01 2020-12-31 NP Sarepta Therapeutics EC US8036071004 2,383 -792 -24.94 406 -8.76 1.6546
2020-11-25 2020-09-30 NP Sarepta Therapeutics EC US8036071004 3,175 209 7.05 446 -6.32 1.8609
2020-08-27 2020-06-30 NP Sarepta Therapeutics EC US8036071004 2,966 -222 -6.96 476 52.73 1.9165
2020-06-01 2020-03-31 NP Sarepta Therapeutics EC US8036071004 3,188 -203 -5.99 312 -28.83 1.9088
2020-03-02 2019-12-31 NP Sarepta Therapeutics EC US8036071004 3,391 -519 -13.27 438 48.64 2.0254
2019-11-27 2019-09-30 NP Sarepta Therapeutics EC US8036071004 3,910 3,910 295 1.5624
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.